Strong Q1 results with accelerating revenue growth and improving margins suggest Zomedica is on track toward cash flow breakeven. Traders should watch for sustained diagnostics growth and further operating leverage in coming quarters.
Price Chart
Executive Summary
Zomedica reported record Q1 2026 revenue of $8.8M (+35% YoY), driven by diagnostics growth (+73%) and consumables (+22%), with net loss improving to $4.5M from $63.8M (no impairment vs $55.8M last year). Adjusted EBITDA loss improved 58% to $2.4M, and cash burn fell 15% to $5.7M, signaling strong operational momentum.
Key Financial Metrics
Key Facts
- Record Q1 revenue of $8.8M, up 35% YoY from $6.5M
- Diagnostics segment revenue grew 73% to $1.0M; consumables revenue up 22% to $5.5M
- Net loss narrowed to $4.5M from $63.8M (no impairment vs $55.8M in Q1 2025)
- Adjusted EBITDA loss improved 58% to $2.4M from $5.7M
- Cash burn reduced 15% to $5.7M; liquidity at $47.5M
- Development Services segment contributed $2.0M revenue (23% of total)
- Boehringer Ingelheim collaboration announced for equine PPID testing
Financial Impact
Revenue beat prior year by $2.3M (+35%); net loss improvement of $59.3M (mostly non-cash impairment); adjusted EBITDA improvement of $3.3M
Risk Factors
- Still unprofitable with ongoing cash burn ($5.7M in Q1)
- Development Services segment is new and may not sustain revenue
- OTC listing limits liquidity and institutional participation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001654954-26-004419 |
| Document: zom_8k.htm | 0001654954-26-004419 |
| Document: 0001654954-26-004419-index-headers.html | 0001654954-26-004419 |
| Document: 0001654954-26-004419-index.html | 0001654954-26-004419 |
| Document: 0001654954-26-004419.txt | 0001654954-26-004419 |
| 8-K Data (Synthetic) | 0001654954-26-004419 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 6, 2026 24w ago | 8-K | $0.1030 $0.0890 | ▼ −13.59% | ▼ −17.43% | $0.0827 (−19.71%) |
Apr 24, 2026 26w ago | DEFA14A | $0.0980 $0.0880 | ▼ −10.20% | ▼ −14.98% | $0.0827 (−15.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers